WALTHAM,
Mass., Dec. 6, 2022 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:
SNDX), a clinical-stage biopharmaceutical company developing an
innovative pipeline of cancer therapies, today announced the
pricing of an underwritten public offering of 6,818,182 shares of
its common stock. The public offering price of each share of common
stock is $22.00. The aggregate gross
proceeds from this offering are expected to be approximately
$150.0 million, before deducting
underwriting discounts and commissions and other offering expenses
payable by Syndax. In addition, Syndax granted the underwriters a
30-day option to purchase up to an additional 1,022,727 shares of
common stock. All of the shares of common stock are being sold by
Syndax. The offering is expected to close on December 9, 2022, subject to customary closing
conditions.
Goldman Sachs & Co. LLC, J.P. Morgan and Cowen are acting as
joint book-running managers for the offering. BTIG and B. Riley
Securities are acting as co-lead managers for the offering.
The shares are being offered pursuant to a "shelf" registration
statement previously filed and declared effective by the Securities
and Exchange Commission (SEC). A preliminary prospectus supplement
and accompanying prospectus relating to the offering will be filed
with the SEC and will be available on the website of the SEC at
www.sec.gov. When available, copies of the preliminary prospectus
supplement, final prospectus supplement and accompanying prospectus
relating to the offering may be obtained from: Goldman Sachs and
Co. LLC, Attention: Prospectus Department, 200 West Street,
New York, NY 10282, telephone:
866-471-2526, facsimile: 212-902-9316 or by emailing
Prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, telephone:
(866) 803-9204, or by emailing prospectus-eq_fi@jpmchase.com; or
Cowen and Company, LLC, c/o Broadridge Financial Solutions,
Attention: Prospectus Department, 1155 Long Island Avenue,
Edgewood, NY 11717, or by
telephone at (833) 297-2926, or by email at
PostSaleManualRequests@broadridge.com.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. Any offer, if at all, will be made only by
means of a prospectus supplement and accompanying prospectus, which
are a part of the effective registration statement.
About Syndax Pharmaceuticals,
Inc.
Syndax Pharmaceuticals is a clinical stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies. Highlights of the Company's pipeline include
revumenib (SNDX-5613), a highly selective inhibitor of the
Menin–MLL binding interaction, and axatilimab, a monoclonal
antibody that blocks the colony stimulating factor 1 (CSF-1)
receptor, both currently in pivotal trials.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend," "believe" and similar expressions (as well as
other words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Syndax's expectations
and assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. These risks and uncertainties include, without
limitation, risks and uncertainties related to market conditions
and satisfaction of customary closing conditions related to the
proposed public offering. There can be no assurance that Syndax
will be able to complete the proposed public offering on the
anticipated terms, or at all. Other factors that may cause Syndax's
actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
Syndax's filings with the U.S. Securities and Exchange
Commission, including the "Risk Factors" sections contained
therein, as well as the risks identified in the registration
statement and the preliminary prospectus supplement relating to the
offering. These forward-looking statements are based on Syndax's
expectations and assumptions as of the date of this press release.
Except as required by law, Syndax assumes no obligation to update
any forward-looking statements contained herein to reflect any
change in expectations, even as new information becomes
available.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-announces-pricing-of-150-million-public-offering-of-common-stock-301696545.html
SOURCE Syndax Pharmaceuticals, Inc.